脐带源间充质干细胞调控血小板减少性紫癜患者脾细胞抗血小板抗体释放的体外研究
|
摘要
目的探讨脐带来源的间充质干细胞(UC-MSC)免疫治疗特发性血小板减少性紫癜(ITP)的临床应用潜能。
方法:体外建立UC-MSC与ITP(8例)及遗传性球形细胞增多症(HS)脾切除患者(3例)的脾脏单个核细胞共培养体系。数天后用酶联免疫吸附试验(ELISA)法检测共培养上清液中IgG型抗血小板抗体(PAIgG)含量的变化。同时,用Brdu掺入法研究UC-MSC对其中部分ITP患者血小板反应性T辅助淋巴细胞增殖的调节作用。另分离12例ITP及8例健康供者外周血单个核细胞(PBMCs),与UC-MSC按1 UC-MSC:10 PBMCs比例体外共培养3—4天后,收获悬浮细胞,再经佛波脂(PMA)、离子霉素及布雷菲德菌素A(BFA)联合刺激4小时后,流式细胞仪检测CD4~+T细胞极化状态(Th1/Th2比例)。
结果:UC-MSC在体外可增强全部ITP患者脾细胞PAIgG的自发性释放。且在低剂量时(1 UC-MSC:100脾细胞)能抑制血小板抗原诱导的PAIgG释放,而在高剂量(1:10)下转为刺激作用。UC-MSC亦能轻微刺激HS患者脾细胞自发性释放PAIgG,促进1例HS病例血小板抗原诱导的PAIgG升高。另外,UC-MSC还能抑制ITP患者血小板反应性T辅助细胞的增殖,并呈现一定的量效关系。而UC-MSC未能明显影响ITP患者及健康人外周血Th细胞极化状态。
结论:UC-MSC可体外影响ITP患者脾细胞释放PAIgG,具体调控机制及临床应用价值尚有待深入研究。
Object To investigate the potential immunotherapeutical effects of umbilical cord-derived mesenchymal stem cells(UC-MSC) on patients with idiopathic thrombocytopenic purpura(ITP),an autoimmune disease characterized by autoantibody-mediated destruction of the platelets by macrophages in the reticuloendothelial system.
Methods Different doses of UC-MSC were cocultured in vitro with splenocytes isolated from eight cases of ITP patients and three cases of hereditary spherocytosis(HS) patients who experienced splenectomy. After a short term culture,the level of IgG antiplatelet antibody(PAIgG) in supernatants was determined by a competitive micro-enzyme-linked immunosorbent assay(ELISA) method.The proliferation of platelet-reactive CD4~+ T lymphocytes was also measured with Brdu incorporation ELISA method after coculture with UC-MSCs for 7 days. In the T subsets experiment,peripheral blood mononuclear cells(PBMCs) were isolated from another 12 chronic ITP patients and 8 healthy donors. After cocultured with UC-MSCs(at the ratio of 1UC-MSC:10 PBMCs) for 3-4 days in vitro,PBMCs were harvested and activated by the combination of PMA,ionomycin and BFA.The ratio of Th1/Th2 was studied by analysis of intracellular cytokines with flow cytometry.
Results UC-MSC could significantly promote the spontaneous secretion of PAIgG by splenocytes from all ITP patients.In the platelet-inducing condition,UC-MSC inhibited the production of PAIgG in splenocytes of ITP patients at a low ratio of 1 UC-MSC to 100 splenocytes,while promoted at 1:10.In contrast,UC-MSC slightly stimulated spontaneous secretion of PAIgG from splenocytes of HS patients.Platelet-induced PAIgG production was enhanced in only one HS sample.In addition,UC-MSC exerted a definitely suppressive effect on the proliferation of platelet-reactive T helper cells in a dose-dependent manner.However,UC-MSCs failed to obviously change the polarization of T cell subsets isolated from PBMCs of ITP patients and healthy donors.
Conclusion UC-MSC can regulate IgG antiplatelet antibodies secretion by splenocytes of ITP patients in vitro,and further study about exact modulation mechanism and prospect for clinical application is expected.
方法:体外建立UC-MSC与ITP(8例)及遗传性球形细胞增多症(HS)脾切除患者(3例)的脾脏单个核细胞共培养体系。数天后用酶联免疫吸附试验(ELISA)法检测共培养上清液中IgG型抗血小板抗体(PAIgG)含量的变化。同时,用Brdu掺入法研究UC-MSC对其中部分ITP患者血小板反应性T辅助淋巴细胞增殖的调节作用。另分离12例ITP及8例健康供者外周血单个核细胞(PBMCs),与UC-MSC按1 UC-MSC:10 PBMCs比例体外共培养3—4天后,收获悬浮细胞,再经佛波脂(PMA)、离子霉素及布雷菲德菌素A(BFA)联合刺激4小时后,流式细胞仪检测CD4~+T细胞极化状态(Th1/Th2比例)。
结果:UC-MSC在体外可增强全部ITP患者脾细胞PAIgG的自发性释放。且在低剂量时(1 UC-MSC:100脾细胞)能抑制血小板抗原诱导的PAIgG释放,而在高剂量(1:10)下转为刺激作用。UC-MSC亦能轻微刺激HS患者脾细胞自发性释放PAIgG,促进1例HS病例血小板抗原诱导的PAIgG升高。另外,UC-MSC还能抑制ITP患者血小板反应性T辅助细胞的增殖,并呈现一定的量效关系。而UC-MSC未能明显影响ITP患者及健康人外周血Th细胞极化状态。
结论:UC-MSC可体外影响ITP患者脾细胞释放PAIgG,具体调控机制及临床应用价值尚有待深入研究。
Object To investigate the potential immunotherapeutical effects of umbilical cord-derived mesenchymal stem cells(UC-MSC) on patients with idiopathic thrombocytopenic purpura(ITP),an autoimmune disease characterized by autoantibody-mediated destruction of the platelets by macrophages in the reticuloendothelial system.
Methods Different doses of UC-MSC were cocultured in vitro with splenocytes isolated from eight cases of ITP patients and three cases of hereditary spherocytosis(HS) patients who experienced splenectomy. After a short term culture,the level of IgG antiplatelet antibody(PAIgG) in supernatants was determined by a competitive micro-enzyme-linked immunosorbent assay(ELISA) method.The proliferation of platelet-reactive CD4~+ T lymphocytes was also measured with Brdu incorporation ELISA method after coculture with UC-MSCs for 7 days. In the T subsets experiment,peripheral blood mononuclear cells(PBMCs) were isolated from another 12 chronic ITP patients and 8 healthy donors. After cocultured with UC-MSCs(at the ratio of 1UC-MSC:10 PBMCs) for 3-4 days in vitro,PBMCs were harvested and activated by the combination of PMA,ionomycin and BFA.The ratio of Th1/Th2 was studied by analysis of intracellular cytokines with flow cytometry.
Results UC-MSC could significantly promote the spontaneous secretion of PAIgG by splenocytes from all ITP patients.In the platelet-inducing condition,UC-MSC inhibited the production of PAIgG in splenocytes of ITP patients at a low ratio of 1 UC-MSC to 100 splenocytes,while promoted at 1:10.In contrast,UC-MSC slightly stimulated spontaneous secretion of PAIgG from splenocytes of HS patients.Platelet-induced PAIgG production was enhanced in only one HS sample.In addition,UC-MSC exerted a definitely suppressive effect on the proliferation of platelet-reactive T helper cells in a dose-dependent manner.However,UC-MSCs failed to obviously change the polarization of T cell subsets isolated from PBMCs of ITP patients and healthy donors.
Conclusion UC-MSC can regulate IgG antiplatelet antibodies secretion by splenocytes of ITP patients in vitro,and further study about exact modulation mechanism and prospect for clinical application is expected.
引文
1. Pittenger MF, Mackay AM, Beck SC. Multilineage potential of human mesenchymal stem cells. science 1999; 284:143-147.
2. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, Muguruma Y,Tsuboi K, Itabashi Y, Ikeda Y, Ogawa S, Okano H, Hotta T, Ando K, Fukuda K.Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004; 104(12):3581-3587.
3. Sato Y, Araki H, Kato J, Nakamura K, Kawano Y, Kobune M, Sato T, Miyanishi K, Takayama T, Takahashi M, Takimoto R, Iyama S, Matsunaga T, Ohtani S, Matsuura A, Hamada H, Niitsu Y. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion.Blood 2005; 106(2):756-763.
4. Jeong JA, Gang EJ, Hong SH, Hwang SH, Kim SW, Yang IH, Ahn C, Han H,Kim H. Rapid neural differentiation of human cord blood-derived mesenchymal stem cells. Neuroreport 2004; 15 (11): 1731-1734.
5. Le BK, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31 (10):890-896.
6. Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res 2006; 312(12):2169-2179.
7. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P,Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood 2002; 99 (10):3838-3843.
8. Le BK, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57(1): 11-20.
9. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101 (9):3722-3 729.
10. Aggarwal S, Pittenger MR Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105 (4): 1815-1822.
11. Fang B, Song YP, Liao LM, Han Q, Zhao RC. Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells. Bone Marrow Transplant 2006; 38(5):389-390.
12. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR,Moseley AB, Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11(5):389-398.
13. Le BK, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M.Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363 (9419): 1439-1441.
14. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103(12):4619-4621.
15. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K.Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109 (1):228-234.
16. Kang XQ, Zang WJ, Bao LJ, Li DL, Xu XL, Yu XJ. Differentiating characterization of human umbilical cord blood-derived mesenchymal stem cells in vitro. Cell Biol Int 2006; 30 (7):569-575.
17. In AP, Scherjon SA, Kleijburg-van KC, Noort WA, Claas FH, Willemze R, Fibbe WE, Kanhai HH. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation.Blood 2003;102(4):1548-1549.
18.De UD,Morizono K,Elbarbary A,Alfonso Z,Zuk PA,Zhu M,Dragoo JL,Ashjian P,Thomas B,Benhaim P,Chen I,Fraser J,Hedrick MH.Comparison of multi-lineage cells from human adipose tissue and bone marrow.Cells Tissues Organs 2003;174(3):101-109.
19.Sarugaser R,Lickorish D,Baksh D,Hosseini MM,Davies JE.Human umbilical cord perivascular(HUCPV' cells:a source of mesenchymal progenitors.Stem Cells 2005;23(2):220-229.
20.D.B,R.Y,RS.T.Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow.Stem Cells 2007;25(6):1384-1392.
21.张浪辉,,刘拥军,,吕璐璐,,王爱萍,许贞书,,朱雄鹏,,陈志哲,,韩忠朝,脐带源间充质干细胞对异源性脐带血T淋巴细胞激活与增殖的抑制作用.中国肿瘤生物治疗杂志2006;13(3).
22.Romanov YA,Svintsitskaya VA,Smirnov VN.Searching for alternative sources of postnatal human mesenchymal stem cells:candidate MSC-like cells from umbilical cord.Stem Cells 2003;21(1):105-110:
23.Cines DB,McMillan R.Pathogenesis of chronic immune thrombocytopenic purpura.Curr Opin Hematol 2007;14(5):511-514.
24.Semple JW,Freedman J.Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia.Blood 1991;78(10):2619-2625.
25.Panitsas FP,Theodoropoulou M,Kouraklis A,Karakantza M,Theodorou GL,Zoumbos NC,Maniatis A,Mouzaki A.Adult chronic idiopathic thrombocytopenic purpura(ITP) is the manifestation of a type-1 polarized immune response.Blood 2004;103(7):2645-2647.
26.Ogawara H,Handa H,Morita K,Hayakawa M,Kojima J,Amagai H,Tsumita Y,Kaneko Y,Tsukamoto N,Nojima Y,Murakami H.High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura.Eur J Haematol 2003;71(4):283-288.
27.张之南,沈悌. 2007.血液诊断及疗效标准.第3版.北京:科学出版社,43-172
28. Sugawara S, Abo T, Kumagai K. A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3. J Immunol Methods 1987; 100 (1-2):83-90.
29. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M,Gualandi F, Mancardi GL, Pistoia V, Uccelli A. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107 (1):367-372.
30. Traggiai E, Volpi S, Schena F, Gattorno M, Ferlito F, Moretta L, Martini A. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008; 26 (2):562-569.
31. Rasmusson I, Le Blanc K, Sundberg B, Ringden O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol 2007; 65(4):336-343.
32. Comoli P, Ginevri F, Maccario R, Avanzini MA, Marconi M, Groff A, Cometa A,Cioni M, Porretti L, Barberi W, Frassoni F, Locatelli F. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation.Nephrol Dial Transplant 2008; 23 (4):1196-1202.
33. Ren H, Zhao H, Wang T, Yang Y, Han Z, Liu B, Wu Z, Tao J, Zhou B, Zhang L.Yang R, Han ZC. Leptin enhances in vitro secretion of IgG antiplatelet antibodies by splenocytes and peripheral blood mononuclear cells from patients with chronic idiopathic thrombocytopenic purpura. Clinical immunology (Orlando, Fla 2006; 120 (2):205-211.
34. Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 2002; 168 (7):3675-3682.
35. McMillan R, Lopez-Dee J, Bowditch R. Clonal restriction of platelet-associated anti-GPIIb/IIIa autoantibodies in patients with chronic ITP. Thromb Haemost 2001; 85 (5):821-823.
36. Majumdar MK, Thiede MA, JD M, Aakula S. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol 1998; 176:57-66.
37. Splawski JB, McAnally LM, PE. L. IL-2 dependence of the promotion of human B cell differentiation by IL-6 (BSF-2). J Immunol 1990; 144:562-569.
38. Muraguchi A, Hirano T, Tang B, P Q. (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167:332-344.
39. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A,Dessoly J, Sciaini AK, Benbunan M, Chomienne C, Fermand JP, Marolleau JP,Larghero J. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007; 21 (1):158-163.
40. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Asian H, Galun E,Rachmilewitz J. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005; 105 (5):2214-2219.
41. Catani L, Fagioli ME, Tazzari PL, Ricci F, Curti A, Rovito M, Preda P,Chirumbolo G, Amabile M, Lemoli RM, Tura S, Conte R, Baccarani M, Vianelli N. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol 2006; 34(7):879-887.
42. Zhang W, Ge W, Li C, You S, Liao L, Han Q, Deng W, Zhao RC. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004; 13 (3):263-271.
43. Powrie F, Coffman RL. Cytokine regulation of T-cell function: potential for therapeutic intervention. Immunol Today 1993; 14 (6):270-274.
44. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16(1):34-38.
45. O'Garra A, Steinman L, Gijbels K. CD4+ T-cell subsets in autoimmunity. Curr Opin Immunol 1997; 9 (6):872-883.
46.Elson CO,Cong Y,Brandwein S,Weaver CT,McCabe RP,Mahler M,Sundberg JP,Leiter EH.Experimental models to study molecular mechanisms underlying intestinal inflammation.Ann N Y Acad Sci 1998;859:85-95.
47.Wang T,Zhao H,Ren H,Guo J,Xu M,Yang R,Han ZC.Type 1 and type 2T-cell profiles in idiopathic thrombocytopenic purpura.Haematologica 2005;90(7):914-923.
48.宣曼,谢晓宝,邱国强.间充质干细胞对不同刺激条件下Th1/Th2细胞比值的影响.基础医学与临床.2006 26(11):1235-8.
1. Pittenger MF, Mackay AM, Beck SC. Multilineage potential of human mesenchymal stem cells. science. 1999; 284:143-147.
2. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276:71-4.
3. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, Muguruma Y, Tsuboi K,Itabashi Y, Ikeda Y, Ogawa S, Okano H, Hotta T, Ando K, Fukuda K. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocyles after myocardial infarction. Blood. 2004; 104:3581-7.
4. Sato Y, Araki H, Kato J, Nakamura K, Kawano Y, Kobune M, Sato T, Miyanishi K,Takayama T, Takahashi M, Takimoto R, Iyama S, Matsunaga T, Ohtani S, Matsuura A,Hamada H, Niitsu Y. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood. 2005; 106:756-63.
5. Jeong JA, Gang EJ, Hong SH, Hwang SH, Kim SW, Yang IH, Ahn C, Han H, Kim H. Rapid neural differentiation of human cord blood-derived mesenchymal stem cells. Neuroreport.2004; 15:1731-4.
6. Kang JH, Lee CK, Kim JR, Yu SJ, Jo JH, Do BR, Kim HK, Kang SG. Estrogen stimulates the neuronal differentiation of human umbilical cord blood mesenchymal stem cells (cd34-).Neuroreport. 2007; 18:35-8.
7. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 1974; 17:331 -40.
8. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, Ruadkow IA. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974; 2:83-92.
9. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA,Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284:143-7.
10. Kang XQ, Zang WJ, Bao LJ, Li DL, Xu XL, Yu XJ. Differentiating characterization of human umbilical cord blood-derived mesenchymal stem cells in vitro. Cell Biol Int. 2006;30:569-75.
11. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, Noort WA, Claas FH, Willemze R,Fibbe WE, Kanhai HH. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood. 2003; 102:1548-9.
12. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M, Dragoo JL, Ashjian P,Thomas B, Benhaim P, Chen I, Fraser J, Hedrick MH. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs. 2003; 174.
13. Guilak F, Awad HA, Fermor B, Leddy HA, Gimble JM. Adipose-derived adult stem cells for cartilage tissue engineering. Biorheology. 2004; 41:389-99.
14. Romanov YA, Svintsitskaya VA, Smirnov VN. Searching for alternative sources of postnatal human mesenchymal stem cells: Candidate msc-like cells from umbilical cord. Stem Cells.2003; 21:105-10.
15. Gang EJ, Bosnakovski D, Figueiredo CA, Visser JW, Perlingeiro RC. Ssea-4 identifies mesenchymal stem cells from bone marrow. Blood. 2007; 109:1743-51.
16. Zhang ZX, Guan LX, Zhang K, Wang S, Cao PC, Wang YH, Wang Z, Dai LJ. Cytogenetic analysis of human bone marrow-derived mesenchymal stem cells passaged in vitro. Cell Biol Int. 2006.
17. Gotherstrom C, Ringden O, Tammik C, Zetterberg E, Westgren M, Le Blanc K.Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol.2004; 190:239-45.
18. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. Hla expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol.2003; 31:890-6.
19. Chan JL, Tang KC, Patel AP, Bonilla LM, Pierobon N, Ponzio NM, Rameshwar P.Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood. 2006; 107:4817-24.
20. Le BK, Tammik C, Rosendahl K, Zetterberg E, Ringden O. Hla expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol.2003; 31:890-6.
21. Gotherstrom C, Ringden O, Tammik C, Zetterberg E, Westgren M, Le BK.. Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol. 2004; 190:239-45.
22. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic t-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation. 2003; 75.
23. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noel D, Jorgensen C.Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003; 102:3837-44.
24. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific t cells to their cognate peptide. Blood. 2003; 101:3722-9.
25. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S,Gianni AM. Human bone marrow stromal cells suppress t-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002; 99.
26. Le BK, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003; 57:11-20.
27. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S,Gianni AM. Human bone marrow stromal cells suppress t-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002; 99:3838-43.
28. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105:1815-22.
29. Prevosto C, Zancolli M, Canevali P, Zocchi MR, A P. Generation of cd4+ or cd8+ regulatoryt cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica. 2007;92:881-8.
30. Tian Y, Deng YB, Huang YJ, Wang Y. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation. Immunol Invest. 2008; 37:29-42.
31. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic t-cell responses by indoleamine 2,3-dioxygenase mediated tryptophan degradation. Blood. 2004; 103.
32. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K. Nitric oxide plays a critical role in suppression of t-cell proliferation by mesenchymal stem cells. Blood.2007; 109:228-34.
33. Traggiai E, Volpi S, Schena F, Gattomo M, Ferlito F, Moretta L, Martini A. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of b cells isolated from healthy donors and systemic lupus erythemaiosus patients. Stem Cells. 2008; 26:562-9.
34. Ichii M, Oritani K, Yokota T, Nishida M, Takahashi I, Shirogane T, Ezoe S, Saitoh N,Tanigawa R, Kincade PW, Kanakura Y. Regulation of human b lymphopoiesis by the transforming growth factor-beta superfamily in a newly established coculture system using human mesenchymal stem cells as a supportive microenvironment. Exp Hematol. 2008.
35. Majumdar MK, Thiede MA, JD M, Aakula S. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (mscs) and stromal cells. J Cell Physiol.1998; 176:57-66.
36. Splawski JB, McAnally LM, PE. L. 11-2 dependence of the promotion of human b cell differentiation by il-6 (bsf-2). J Immunol. 1990; 144:562-569.
37. Muraguchi A, Hirano T, Tang B, P Q. (bsf-2/il-6) for the terminal differentiation of b cells. J Exp Med. 1988; 167:332-344.
38. Amulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MM, Crinquette A, Dessoly J, Sciaini AK., Benbunan M, Chomienne C, Fermand JP, Marolleau JP, Larghero J. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia. 2007; 21:158-63.
39. Mudry RE, Fortney JE, York T, Hall BM, Gibson LF. Stromal cells regulate survival of b-lineage leukemic cells during chemotherapy. Blood. 2000; 96:1926-32.
40. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V, Uccelli A. Human mesenchymal stem cells modulate b-cell functions. Blood. 2006; 107:367-72.
41. Comoli P, Ginevri F, Maccario R, Avanzini MA, Marconi M, Groff A, Cometa A, Cioni M, Porretti L, Barberi W, Frassoni F, Locatelli F. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant. 2008;23:1196-202.
42. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006;24:74-85.
43. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: Evidence that activated nk cells are capable of killing mscs, whereas mscs can inhibit il-2-induced nk-cell proliferation. Blood. 2006;107:1484-90.
44. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Asian H, Galun E, Rachmilewitz J. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce t-cell unresponsiveness. Blood. 2005; 105:2214-9.
45. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005;105:4120-6.
46. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, Daudt L, Ibatici A,Piaggio G, Pozzi S, Frassoni F, Locatelli F. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of cd4+ t-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005;90:516-25.
47. Bacigalupo A, Valle M, Podesta M, Pitto A, Zocchi E, De FA, Pozzi S, Luchetti S, Frassoni F, Van LM, Piaggio G. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol. 2005; 33:819-27.
48. Sun LY, Zhang HY, Feng XB, Hou YY, Lu LW, Fan LM. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus.Lupus. 2007; 16:121-8.
49. Kastrinaki MC, Sidiropoulos P, Roche S, Ringe J, Lehmann S, Kritikos H, Vlahava VM,Delorme B, Eliopoulos GD, Jorgensen C, Charbord P, Haupl T, Boumpas DT, Papadaki HA.Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis. 2008; 67:741-9.
50. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing t-cell anergy. Blood. 2005;106:1755-61.
51. Gerdoni E, Gallo B, Casazza S, Musio S, Bonanni I, Pedemonte E, Mantegazza R, Frassoni F, Mancardi G, Pedotti R, Uccelli A. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol.2007; 61:219-27.
52. Deng W, Han Q, Liao L, You S, Deng H, Zhao RC. Effects of allogeneic bone marrow-derived mesenchymal stem cells on t and b lymphocytes from bxsb mice. DNA Cell Biol. 2005; 24:458-63.
53. Jorgensen C, Djouad F, Fritz V, Apparailly F, Plence P, Noel D. Mesenchymal stem cells and rheumatoid arthritis. Joint Bone Spine. 2003; 70:483-5.
54. Troeger A, Meisel R, Moritz T, Dilloo D. Immunotherapy in allogeneic hematopoietic stem cell transplantation～not just a case for effector cells. Bone Marrow Transplant. 2005; 35 Suppl 1 :S59-64.
55. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O.Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004; 363:1439-41.
56. Fang B, Song YP, Liao LM, Han Q, Zhao RC. Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells. Bone Marrow Transplant. 2006; 38:389-90.
57. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ,McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR, Jr., Moseley AB, Bacigalupo A. Cotransplantation of hla-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.Biol Blood Marrow Transplant. 2005; 11:389-98.
58. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B,Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase ii study. Lancet. 2008; 371:1579-86.
59. Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: Impact on in vivo tumor growth.Leukemia. 2007; 21:304-10.
60. Sundin M, Orvell C, Rasmusson I, Sundberg B, Ringden O, Le Blanc K. Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplant. 2006; 37:1051-9.
61. Smirnov SV, Harbacheuski R, Lewis-Antes A, Zhu H, Rameshwar P, Kotenko SV.Bone-marrow-derived mesenchymal stem cells as a target for cytomegalovirus infection:Implications for hematopoiesis, self-renewal and differentiation potential. Virology. 2007;360:6-16.
2. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, Muguruma Y,Tsuboi K, Itabashi Y, Ikeda Y, Ogawa S, Okano H, Hotta T, Ando K, Fukuda K.Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004; 104(12):3581-3587.
3. Sato Y, Araki H, Kato J, Nakamura K, Kawano Y, Kobune M, Sato T, Miyanishi K, Takayama T, Takahashi M, Takimoto R, Iyama S, Matsunaga T, Ohtani S, Matsuura A, Hamada H, Niitsu Y. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion.Blood 2005; 106(2):756-763.
4. Jeong JA, Gang EJ, Hong SH, Hwang SH, Kim SW, Yang IH, Ahn C, Han H,Kim H. Rapid neural differentiation of human cord blood-derived mesenchymal stem cells. Neuroreport 2004; 15 (11): 1731-1734.
5. Le BK, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31 (10):890-896.
6. Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res 2006; 312(12):2169-2179.
7. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P,Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood 2002; 99 (10):3838-3843.
8. Le BK, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57(1): 11-20.
9. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101 (9):3722-3 729.
10. Aggarwal S, Pittenger MR Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105 (4): 1815-1822.
11. Fang B, Song YP, Liao LM, Han Q, Zhao RC. Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells. Bone Marrow Transplant 2006; 38(5):389-390.
12. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR,Moseley AB, Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11(5):389-398.
13. Le BK, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M.Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363 (9419): 1439-1441.
14. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103(12):4619-4621.
15. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K.Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109 (1):228-234.
16. Kang XQ, Zang WJ, Bao LJ, Li DL, Xu XL, Yu XJ. Differentiating characterization of human umbilical cord blood-derived mesenchymal stem cells in vitro. Cell Biol Int 2006; 30 (7):569-575.
17. In AP, Scherjon SA, Kleijburg-van KC, Noort WA, Claas FH, Willemze R, Fibbe WE, Kanhai HH. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation.Blood 2003;102(4):1548-1549.
18.De UD,Morizono K,Elbarbary A,Alfonso Z,Zuk PA,Zhu M,Dragoo JL,Ashjian P,Thomas B,Benhaim P,Chen I,Fraser J,Hedrick MH.Comparison of multi-lineage cells from human adipose tissue and bone marrow.Cells Tissues Organs 2003;174(3):101-109.
19.Sarugaser R,Lickorish D,Baksh D,Hosseini MM,Davies JE.Human umbilical cord perivascular(HUCPV' cells:a source of mesenchymal progenitors.Stem Cells 2005;23(2):220-229.
20.D.B,R.Y,RS.T.Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow.Stem Cells 2007;25(6):1384-1392.
21.张浪辉,,刘拥军,,吕璐璐,,王爱萍,许贞书,,朱雄鹏,,陈志哲,,韩忠朝,脐带源间充质干细胞对异源性脐带血T淋巴细胞激活与增殖的抑制作用.中国肿瘤生物治疗杂志2006;13(3).
22.Romanov YA,Svintsitskaya VA,Smirnov VN.Searching for alternative sources of postnatal human mesenchymal stem cells:candidate MSC-like cells from umbilical cord.Stem Cells 2003;21(1):105-110:
23.Cines DB,McMillan R.Pathogenesis of chronic immune thrombocytopenic purpura.Curr Opin Hematol 2007;14(5):511-514.
24.Semple JW,Freedman J.Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia.Blood 1991;78(10):2619-2625.
25.Panitsas FP,Theodoropoulou M,Kouraklis A,Karakantza M,Theodorou GL,Zoumbos NC,Maniatis A,Mouzaki A.Adult chronic idiopathic thrombocytopenic purpura(ITP) is the manifestation of a type-1 polarized immune response.Blood 2004;103(7):2645-2647.
26.Ogawara H,Handa H,Morita K,Hayakawa M,Kojima J,Amagai H,Tsumita Y,Kaneko Y,Tsukamoto N,Nojima Y,Murakami H.High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura.Eur J Haematol 2003;71(4):283-288.
27.张之南,沈悌. 2007.血液诊断及疗效标准.第3版.北京:科学出版社,43-172
28. Sugawara S, Abo T, Kumagai K. A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3. J Immunol Methods 1987; 100 (1-2):83-90.
29. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M,Gualandi F, Mancardi GL, Pistoia V, Uccelli A. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107 (1):367-372.
30. Traggiai E, Volpi S, Schena F, Gattorno M, Ferlito F, Moretta L, Martini A. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008; 26 (2):562-569.
31. Rasmusson I, Le Blanc K, Sundberg B, Ringden O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol 2007; 65(4):336-343.
32. Comoli P, Ginevri F, Maccario R, Avanzini MA, Marconi M, Groff A, Cometa A,Cioni M, Porretti L, Barberi W, Frassoni F, Locatelli F. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation.Nephrol Dial Transplant 2008; 23 (4):1196-1202.
33. Ren H, Zhao H, Wang T, Yang Y, Han Z, Liu B, Wu Z, Tao J, Zhou B, Zhang L.Yang R, Han ZC. Leptin enhances in vitro secretion of IgG antiplatelet antibodies by splenocytes and peripheral blood mononuclear cells from patients with chronic idiopathic thrombocytopenic purpura. Clinical immunology (Orlando, Fla 2006; 120 (2):205-211.
34. Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 2002; 168 (7):3675-3682.
35. McMillan R, Lopez-Dee J, Bowditch R. Clonal restriction of platelet-associated anti-GPIIb/IIIa autoantibodies in patients with chronic ITP. Thromb Haemost 2001; 85 (5):821-823.
36. Majumdar MK, Thiede MA, JD M, Aakula S. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol 1998; 176:57-66.
37. Splawski JB, McAnally LM, PE. L. IL-2 dependence of the promotion of human B cell differentiation by IL-6 (BSF-2). J Immunol 1990; 144:562-569.
38. Muraguchi A, Hirano T, Tang B, P Q. (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167:332-344.
39. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A,Dessoly J, Sciaini AK, Benbunan M, Chomienne C, Fermand JP, Marolleau JP,Larghero J. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007; 21 (1):158-163.
40. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Asian H, Galun E,Rachmilewitz J. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005; 105 (5):2214-2219.
41. Catani L, Fagioli ME, Tazzari PL, Ricci F, Curti A, Rovito M, Preda P,Chirumbolo G, Amabile M, Lemoli RM, Tura S, Conte R, Baccarani M, Vianelli N. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol 2006; 34(7):879-887.
42. Zhang W, Ge W, Li C, You S, Liao L, Han Q, Deng W, Zhao RC. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004; 13 (3):263-271.
43. Powrie F, Coffman RL. Cytokine regulation of T-cell function: potential for therapeutic intervention. Immunol Today 1993; 14 (6):270-274.
44. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16(1):34-38.
45. O'Garra A, Steinman L, Gijbels K. CD4+ T-cell subsets in autoimmunity. Curr Opin Immunol 1997; 9 (6):872-883.
46.Elson CO,Cong Y,Brandwein S,Weaver CT,McCabe RP,Mahler M,Sundberg JP,Leiter EH.Experimental models to study molecular mechanisms underlying intestinal inflammation.Ann N Y Acad Sci 1998;859:85-95.
47.Wang T,Zhao H,Ren H,Guo J,Xu M,Yang R,Han ZC.Type 1 and type 2T-cell profiles in idiopathic thrombocytopenic purpura.Haematologica 2005;90(7):914-923.
48.宣曼,谢晓宝,邱国强.间充质干细胞对不同刺激条件下Th1/Th2细胞比值的影响.基础医学与临床.2006 26(11):1235-8.
1. Pittenger MF, Mackay AM, Beck SC. Multilineage potential of human mesenchymal stem cells. science. 1999; 284:143-147.
2. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276:71-4.
3. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, Muguruma Y, Tsuboi K,Itabashi Y, Ikeda Y, Ogawa S, Okano H, Hotta T, Ando K, Fukuda K. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocyles after myocardial infarction. Blood. 2004; 104:3581-7.
4. Sato Y, Araki H, Kato J, Nakamura K, Kawano Y, Kobune M, Sato T, Miyanishi K,Takayama T, Takahashi M, Takimoto R, Iyama S, Matsunaga T, Ohtani S, Matsuura A,Hamada H, Niitsu Y. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood. 2005; 106:756-63.
5. Jeong JA, Gang EJ, Hong SH, Hwang SH, Kim SW, Yang IH, Ahn C, Han H, Kim H. Rapid neural differentiation of human cord blood-derived mesenchymal stem cells. Neuroreport.2004; 15:1731-4.
6. Kang JH, Lee CK, Kim JR, Yu SJ, Jo JH, Do BR, Kim HK, Kang SG. Estrogen stimulates the neuronal differentiation of human umbilical cord blood mesenchymal stem cells (cd34-).Neuroreport. 2007; 18:35-8.
7. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 1974; 17:331 -40.
8. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, Ruadkow IA. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974; 2:83-92.
9. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA,Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284:143-7.
10. Kang XQ, Zang WJ, Bao LJ, Li DL, Xu XL, Yu XJ. Differentiating characterization of human umbilical cord blood-derived mesenchymal stem cells in vitro. Cell Biol Int. 2006;30:569-75.
11. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, Noort WA, Claas FH, Willemze R,Fibbe WE, Kanhai HH. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood. 2003; 102:1548-9.
12. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M, Dragoo JL, Ashjian P,Thomas B, Benhaim P, Chen I, Fraser J, Hedrick MH. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs. 2003; 174.
13. Guilak F, Awad HA, Fermor B, Leddy HA, Gimble JM. Adipose-derived adult stem cells for cartilage tissue engineering. Biorheology. 2004; 41:389-99.
14. Romanov YA, Svintsitskaya VA, Smirnov VN. Searching for alternative sources of postnatal human mesenchymal stem cells: Candidate msc-like cells from umbilical cord. Stem Cells.2003; 21:105-10.
15. Gang EJ, Bosnakovski D, Figueiredo CA, Visser JW, Perlingeiro RC. Ssea-4 identifies mesenchymal stem cells from bone marrow. Blood. 2007; 109:1743-51.
16. Zhang ZX, Guan LX, Zhang K, Wang S, Cao PC, Wang YH, Wang Z, Dai LJ. Cytogenetic analysis of human bone marrow-derived mesenchymal stem cells passaged in vitro. Cell Biol Int. 2006.
17. Gotherstrom C, Ringden O, Tammik C, Zetterberg E, Westgren M, Le Blanc K.Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol.2004; 190:239-45.
18. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. Hla expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol.2003; 31:890-6.
19. Chan JL, Tang KC, Patel AP, Bonilla LM, Pierobon N, Ponzio NM, Rameshwar P.Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood. 2006; 107:4817-24.
20. Le BK, Tammik C, Rosendahl K, Zetterberg E, Ringden O. Hla expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol.2003; 31:890-6.
21. Gotherstrom C, Ringden O, Tammik C, Zetterberg E, Westgren M, Le BK.. Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol. 2004; 190:239-45.
22. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic t-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation. 2003; 75.
23. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noel D, Jorgensen C.Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003; 102:3837-44.
24. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific t cells to their cognate peptide. Blood. 2003; 101:3722-9.
25. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S,Gianni AM. Human bone marrow stromal cells suppress t-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002; 99.
26. Le BK, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003; 57:11-20.
27. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S,Gianni AM. Human bone marrow stromal cells suppress t-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002; 99:3838-43.
28. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105:1815-22.
29. Prevosto C, Zancolli M, Canevali P, Zocchi MR, A P. Generation of cd4+ or cd8+ regulatoryt cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica. 2007;92:881-8.
30. Tian Y, Deng YB, Huang YJ, Wang Y. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation. Immunol Invest. 2008; 37:29-42.
31. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic t-cell responses by indoleamine 2,3-dioxygenase mediated tryptophan degradation. Blood. 2004; 103.
32. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K. Nitric oxide plays a critical role in suppression of t-cell proliferation by mesenchymal stem cells. Blood.2007; 109:228-34.
33. Traggiai E, Volpi S, Schena F, Gattomo M, Ferlito F, Moretta L, Martini A. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of b cells isolated from healthy donors and systemic lupus erythemaiosus patients. Stem Cells. 2008; 26:562-9.
34. Ichii M, Oritani K, Yokota T, Nishida M, Takahashi I, Shirogane T, Ezoe S, Saitoh N,Tanigawa R, Kincade PW, Kanakura Y. Regulation of human b lymphopoiesis by the transforming growth factor-beta superfamily in a newly established coculture system using human mesenchymal stem cells as a supportive microenvironment. Exp Hematol. 2008.
35. Majumdar MK, Thiede MA, JD M, Aakula S. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (mscs) and stromal cells. J Cell Physiol.1998; 176:57-66.
36. Splawski JB, McAnally LM, PE. L. 11-2 dependence of the promotion of human b cell differentiation by il-6 (bsf-2). J Immunol. 1990; 144:562-569.
37. Muraguchi A, Hirano T, Tang B, P Q. (bsf-2/il-6) for the terminal differentiation of b cells. J Exp Med. 1988; 167:332-344.
38. Amulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MM, Crinquette A, Dessoly J, Sciaini AK., Benbunan M, Chomienne C, Fermand JP, Marolleau JP, Larghero J. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia. 2007; 21:158-63.
39. Mudry RE, Fortney JE, York T, Hall BM, Gibson LF. Stromal cells regulate survival of b-lineage leukemic cells during chemotherapy. Blood. 2000; 96:1926-32.
40. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V, Uccelli A. Human mesenchymal stem cells modulate b-cell functions. Blood. 2006; 107:367-72.
41. Comoli P, Ginevri F, Maccario R, Avanzini MA, Marconi M, Groff A, Cometa A, Cioni M, Porretti L, Barberi W, Frassoni F, Locatelli F. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant. 2008;23:1196-202.
42. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006;24:74-85.
43. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: Evidence that activated nk cells are capable of killing mscs, whereas mscs can inhibit il-2-induced nk-cell proliferation. Blood. 2006;107:1484-90.
44. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Asian H, Galun E, Rachmilewitz J. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce t-cell unresponsiveness. Blood. 2005; 105:2214-9.
45. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005;105:4120-6.
46. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, Daudt L, Ibatici A,Piaggio G, Pozzi S, Frassoni F, Locatelli F. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of cd4+ t-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005;90:516-25.
47. Bacigalupo A, Valle M, Podesta M, Pitto A, Zocchi E, De FA, Pozzi S, Luchetti S, Frassoni F, Van LM, Piaggio G. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol. 2005; 33:819-27.
48. Sun LY, Zhang HY, Feng XB, Hou YY, Lu LW, Fan LM. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus.Lupus. 2007; 16:121-8.
49. Kastrinaki MC, Sidiropoulos P, Roche S, Ringe J, Lehmann S, Kritikos H, Vlahava VM,Delorme B, Eliopoulos GD, Jorgensen C, Charbord P, Haupl T, Boumpas DT, Papadaki HA.Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis. 2008; 67:741-9.
50. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing t-cell anergy. Blood. 2005;106:1755-61.
51. Gerdoni E, Gallo B, Casazza S, Musio S, Bonanni I, Pedemonte E, Mantegazza R, Frassoni F, Mancardi G, Pedotti R, Uccelli A. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol.2007; 61:219-27.
52. Deng W, Han Q, Liao L, You S, Deng H, Zhao RC. Effects of allogeneic bone marrow-derived mesenchymal stem cells on t and b lymphocytes from bxsb mice. DNA Cell Biol. 2005; 24:458-63.
53. Jorgensen C, Djouad F, Fritz V, Apparailly F, Plence P, Noel D. Mesenchymal stem cells and rheumatoid arthritis. Joint Bone Spine. 2003; 70:483-5.
54. Troeger A, Meisel R, Moritz T, Dilloo D. Immunotherapy in allogeneic hematopoietic stem cell transplantation～not just a case for effector cells. Bone Marrow Transplant. 2005; 35 Suppl 1 :S59-64.
55. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O.Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004; 363:1439-41.
56. Fang B, Song YP, Liao LM, Han Q, Zhao RC. Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells. Bone Marrow Transplant. 2006; 38:389-90.
57. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ,McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR, Jr., Moseley AB, Bacigalupo A. Cotransplantation of hla-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.Biol Blood Marrow Transplant. 2005; 11:389-98.
58. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B,Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase ii study. Lancet. 2008; 371:1579-86.
59. Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: Impact on in vivo tumor growth.Leukemia. 2007; 21:304-10.
60. Sundin M, Orvell C, Rasmusson I, Sundberg B, Ringden O, Le Blanc K. Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplant. 2006; 37:1051-9.
61. Smirnov SV, Harbacheuski R, Lewis-Antes A, Zhu H, Rameshwar P, Kotenko SV.Bone-marrow-derived mesenchymal stem cells as a target for cytomegalovirus infection:Implications for hematopoiesis, self-renewal and differentiation potential. Virology. 2007;360:6-16.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |